Endoscopic sleeve gastroplasty resulted in significant, sustained weight loss in patients with any degree of obesity. The greatest effect was achieved in people with stage III obesity. In these patients, body mass index continued to decline throughout the observation period.
Scientists from the Mayo Clinic in Rochester and the University of Texas assessed the effectiveness and safety of endoscopic sleeve gastroplasty in obese people. The study results were published in the journal Clinical and Translational Gastroenterology.
|The study included 1506 patients. Obesity of I degree was detected in 501 participants, II degree – in 546, III degree – in 459 people. The patients tolerated the procedure well, which was characterized by low invasiveness and trauma.
After 12 months, the vast majority of participants (83.2%) recorded a decrease in total body weight of 10% or more. At the same time, in 60.9%, total body weight decreased by 15% or more.
The degree of weight loss depended on the initial degree of obesity. Among people with grade III obesity, the decrease significantly exceeded the corresponding values in the groups of patients with grades I and II throughout the entire observation period. After two years, in patients with stage III obesity, the average decrease in total body weight was 20.4%. The average reduction among participants with degrees I and II obesity was 13.3 and 13.6%, respectively.
A decrease in body mass index (BMI) was recorded within six months after surgery. The indicator remained stable over the next two years. However, the decrease in BMI during the entire observation period persisted only in patients with stage III obesity.
There were no differences in the incidence of adverse events between groups. Adverse events requiring hospitalization were recorded in only 2.6% of patients, in which the majority of therapeutic measures (86%) consisted of symptomatic therapy and/or fluid volume restoration.